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Pefloxacin (a novel quinolone antibiotic) is demonstrated to be a drug inhibiting DNA replication 
IO-times more efficiently than oxolinic acid measured either in toluene-treated E. coli or in an in vitro 
replication system for oriC plasmids [6]. DNA repair synthesis is not inhibited by the drug. 
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1. INTRODUCTION 
Pefloxacin is a novel quinolone having a power- 
ful antibacterial action [l] (fig.1). The quinolone 
drugs, like nalidixic acid, oxolinic acid, pipemidic 
acid or piromidic acid are specific inhibitors of 
bacterial type II DNA topoisomerases [2]; their 
primary target is one of the subunits of these en- 
zymes (which bears a nicking-closing activity). 
Both in vivo and in vitro, the quinolone drugs 
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Fig. 1. Chemical structures of some quinolones. 
Pefloxacin (1589RB) was obtained from Roger 
Bellon Laboratories; nalidixic acid was obtained 
from Winthrop and oxolinic acid from Dr 
Staudenbauer, Max Planck Institut (Berlin). 
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block DNA replication at low concentrations; at 
higher concentrations DNA transcription is also 
affected [3]. For a long time, nalidixic acid has 
been the only well studied compound; more re- 
cently however, oxolinic acid, which is a more po- 
tent inhibitor both in vivo and in vitro has been 
preferentially used to study DNA replication [4,5]. 
Like oxolinic acid, pefloxacin is a stronger antibac- 
terial agent than nalidixic acid in vivo. The inhibi- 
tion of bacterial growth, DNA, RNA and protein 
synthesis by pefloxacin occurs at concentrations 
two orders of magnitude lower compared to 
nalidixic acid and one order of magnitude lower 
than pipemidic acid [ 11. The results presented in 
this paper show that pefloxacin is also a much 
more potent inhibitor than nalidixic acid of Es- 
cherichia coli DNA replication in situ, in a 
toluenized cell system, and in vitro in the new sys- 
tem of initiation using a crude extract which. repli- 
cates an exogenous oriC plasmid [6]. Furthermore, 
in both systems pefloxacin inhibits DNA replica- 
tion at doses ten times lower than oxolinic acid it- 
self. 
2. MATERIALS AND METHODS 
2.1. Drugs 
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2.2. Bacterial strains pglml; creatine kinase, 100 g/ml; creatine phos- 
Escherichia coli K12H560 (F-pal A-, endo II, phate, 21.6 mM; dATP, dCTP, dGTP and dTTP, 
thy-) and parental strain AB1157 were used in this each 100 PM with [methyl-3H]dTTP at 100 cpm per 
study. Spontaneous Nal’ mutants were isolated by pmol of total deoxynucleotide; dithiothreitol, 
their ability to grow in the presence of 20 pg/ml 4 mM; KCl, 0.1 M; Mg(OAc)l, 11 mM and POC 
nalidixic acid. 42 supercoiled DNA, 8.6 pg/ml. Polyethylenegly- 
co1 6000 was added to a final concentration of 5% 
2.3. Methods 
Cells were grown in Luria broth at 37°C to 
5 x 10s cells/ml and harvested at 4°C. 
Toluenized cells: cells were resuspended to 1010 
cells/ml in 100 mM phosphate buffer (pH 7.4) 
containing 2 mM MgC12 and 1% toluene, per- 
meabilized for 2 min at room temperature by 
Vortex treatment and immediately assayed for 
DNA synthesis as previously described [7]. 
In vitro system: active enzyme extracts were pre- 
pared according to the procedure of Kornberg [6]. 
DNA replication was assayed in a 50 (~1 reaction 
mixture containing the following components: 
N-2-hydroxyethylpiperazine-N’-2 ethane sulfonic 
acid (pH 7.6) 40 mM; ATP, 2 mM; GTP, CTP 
and UTP, each 500 (LM; bovine serum albumin, 50 
to 6% (wt/vol). The reactions were initiated by ad- 
dition of 200-300 pg of protein and incubated at 
30°C for 30 min. Total nucleotide incorporation 
was measured by determining radioactivity after 
trichloroacetic acid precipitation. 
3. RESULTS 
3.1. Effect of pejloxacin on DNA synthesis in 
toluene treated cells 
The experiment described in fig.2a shows the 
comparative effects of various concentrations of 
pefloxacin, oxolinic acid and nalidixic acid on 
DNA replication in toluenized E. cofi cells carry- 
ing a deficient DNA polymerase I activity (pal A-). 
It can be seen that pefloxacin inhibits -50% of 
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Fig.2. Effect of nalidixic acid (m) oxolinic acid (A),and pefloxacin (0) on DNA synthesis in toluenized cells. 2.5 X IO* 
toluenized cells of E. coli H560 N&S (a) or Nulr (b) were incubated in 175 ~1 of incubation mixture (30 mM Tris - HCI 
(pH 7.5) 3.4 mM MgC12, 110 mM KCl, 0.7 mM /3-mercaptoethanol, 1.1 mM ATP and 22 PM each dATP, dGTP, dCTP 
and 13H]dTTP (90 cpm/pmol) with the drug concentrations indicated. After 60 min at 30°C acid insoluble radioactivity 
was determined. 
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replicative DNA synthesis at a drug concentration 
of 0.20 &ml whereas a lo-fold higher concentra- 
tion of oxolinic acid and a 220-fold higher concen- 
tration of nalidixic acid are required to achieve the 
same effect. Furthermore, in contrast with the re- 
sults obtained with nalidixic acid, absolutely no re- 
sidual replication occurs at high concentration of 
pefloxacin. 
The experiment described in tig.2b shows that 
pefloxacin interacts most likely with the same tar- 
get as nalidixic acid. In this experiment, we com- 
pared the effects of pefloxacin and nalidixic acid 
on DNA replication in a toluene treated spon- 
taneous mutant of E. coli that is resistant o high 
concentration of nalidixic acid (Nul’). It can be 
seen from the comparison between the results of 
tig.2a and b that DNA replication in the Nal’ mu- 
tant becomes more resistant o both nalidixic acid 
and pefloxacin. 
It was important to test if pefloxacin shared 
with nalidixic and oxolinic acid a complete specif- 
icity for DNA replication, i.e., no effect on repair 
DNA synthesis. 
An extensive repair like type DNA synthesis 
performed by DNA polymerase I can be induced 
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Fig.3. Selective inhibition of ATP dependent DNA syn- 
thesis by pefloxacin. 2.5 x lo8 toluenized cells of E. coli 
ABI 157 were incubated as described in fig.2 for 60 min 
at 30°C (m) with different concentrations of pefloxacin. 
Repair synthesis (o) was assayed in the same incubation 
mixture without KC1 and /I-mercaptoethanol in the 
presence of 7.9 mM NEM and absence of ATP for 
60 min at 40°C. 
in pol A+ toluene treated cells at 40°C in the ab- 
sence of ATP, and by the addition of N-ethyl 
maleimide (NEM) [8]. In these conditions the rep- 
licative DNA synthesis is completely inhibited 
both by the lack of ATP and by the sulfhydryl 
blocking agent (NEM). However, at 30°C in the 
presence of ATP and in the absence of NEM, 
DNA replication can be measured by adding ATP 
and precursors. Thus by changing these three fac- 
tors, both DNA replication and repair can be mea- 
sured in the same culture. As can be seen in fig.3, 
replicative DNA synthesis is completely inhibited 
by pefloxacin in the same way as in pol A- mutant 
(Iig.2a). In contrast fig.3 shows that, under condi- 
tions which induce DNA repair like synthesis, the 
activity is completely resistant to even very high 
doses of pefloxacin. The same results are obtained 
with nalidixic and oxolinic acid (data not shown). 
3.2. Effect of peji’oxacin on in vitro DNA replica- 
tion of an oriC plasmid 
Recently, an enzyme system that replicates plas- 
mids bearing the origin of the E. coli chromosome 
has been successfully devised [6]. This enzyme sys- 
tems performs the physiological process of chro- 
mosomal initiation in vitro coupled with DNA 
elongation. The DNA gyrase inhibitors, nalidixic 
acid and novobiocin, block DNA replication of the 
oriC plasmid in vitro [6]. We have successfully re- 
peated this system using the POC 42 plasmid DNA 
(a chimere of PBR 322 and a 1.9 kbp fragment 
containing oriC [9]). PBR 322 DNA is not repli- 
cated with this system, demonstrating the impor- 
tance of oriC. Fig.4a shows that pefloxacin com- 
pletely inhibits DNA replication of the oriC 
plasmid POC42 at doses similar to that required to 
inhibit DNA replication in toluene treated cells; 
also similar is the relative efficiency of the two in- 
hibitors, nalidixic acid and pefloxacin. Fig.4b 
shows that when the enzyme system is prepared 
from a spontaneously isolated nalidixic resistant 
strain, DNA replication of the oriC plasmid be- 
comes resistant o all three drugs. It can be seen as 
in fig.2, that cross resistance between pefloxacin 
and nalidixic acid is not complete. When the en- 
zyme is prepared from a pal A+ strains, it contains 
DNA polymerase I activity as revealed by addi- 
tions of both poly(dAT) and NEM (l&3 M). This 
activity is completely resistant to pefloxacin. 
Pefloxacin appears therefore to be a novel and 
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Fig.4. Effect of nalidixic acid (m) oxolinic acid (A) and pefloxacin (0) on in vitro DNA synthesis. Protein extracts ob- 
tained from E. coli H560 (a) and H560 NulT (b) strain containing POC42 plasmid were incubated as described in 
Materials and Methods. 
very strong inhibitor of DNA replication both in 
vivo and in vitro which interacts specifically with 
the same target as nalidixic and oxolinic acid but 
with better efficiency. 
4. DISCUSSION 
We have shown that pefloxacin is a more potent 
inhibitor than nalidixic acid and oxolinic acid of 
DNA replication in vitro both with a per- 
meabilized cell system which performs only DNA 
elongation and in a crude enzyme system which 
performs both the initiation and elongation stage 
of oriC plasmid DNA replication. There is a good 
correlation between the antibacterial activity of 
these drugs and their capacity to block DNA syn- 
thesis in vitro. Pefloxacin is one hundred times 
more active than nalidixic acid and ten times more 
active than oxolinic acid. Doses of the drug as low 
as 5 pg/ml are sufficient to completely inhibit 
DNA replication in vitro. In contrast, even a very 
high dose of pefloxacin failed to repress repair 
type DNA synthesis carried out by DNA poly- 
merase I. This antibiotic is therefore a specific in- 
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hibitor for DNA replication. Cross-resistance of 
spontaneously isolated nalidixic acid resistant mu- 
tants with pefloxacin have suggested that both 
drugs interact in vivo with the same target [ 11. The 
situation observed in vitro indicates that peflox- 
acin must likely interact with the &vrA gene prod- 
uct both in vivo and in vitro. All these data made 
pefloxacin a very attractive compound to study the 
various roles of DNA topoisomerase II in bacterial 
life cycle. Pefloxacin may be also an important tool 
for the elucidation of the precise mode of action of 
quinolone antibacterial agents. Although the mode 
of action of nalidixic acid and its derivatives has 
been intensively studied for more than 15 years 
and in spite of the recent advances stimulated by 
the discoveries of their intracellular protein target, 
many questions remain to be resolved concerning 
the various mechanisms by which these drugs seem 
to alter DNA metabolism [3,7,10]. 
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